Gilead Joins Up With Yale In Cancer Discovery Collaboration
This article was originally published in The Pink Sheet Daily
The biotech has partnered with Yale University on cancer research in a deal that could provide $100 million in funding to Yale over 10 years.
You may also be interested in...
Gilead will buy the Canadian cancer specialist for $510 million, gaining the lead drug CYT387, a JAK1/JAK2 inhibitor that has demonstrated positive results in myelofibrosis patients.
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
New York deals follow UCSF tie-up in San Francisco; six more city-based alliances are to come.